加强术后恢复对尿路膀胱癌根治性膀胱切除术的疗效的影响

IF 2.3 4区 医学 Q3 ONCOLOGY Surgical Oncology-Oxford Pub Date : 2024-03-08 DOI:10.1016/j.suronc.2024.102061
Runzhuo Ma, Farshad Sheybaee Moghaddam, Alireza Ghoreifi, Sanam Ladi-Seyedian, Jie Cai, Gus Miranda, Monish Aron, Anne Schuckman, Mihir Desai, Inderbir Gill, Siamak Daneshmand, Hooman Djaladat
{"title":"加强术后恢复对尿路膀胱癌根治性膀胱切除术的疗效的影响","authors":"Runzhuo Ma,&nbsp;Farshad Sheybaee Moghaddam,&nbsp;Alireza Ghoreifi,&nbsp;Sanam Ladi-Seyedian,&nbsp;Jie Cai,&nbsp;Gus Miranda,&nbsp;Monish Aron,&nbsp;Anne Schuckman,&nbsp;Mihir Desai,&nbsp;Inderbir Gill,&nbsp;Siamak Daneshmand,&nbsp;Hooman Djaladat","doi":"10.1016/j.suronc.2024.102061","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Limited data are available regarding the effect of enhanced recovery after surgery (ERAS) protocols on the long-term outcomes of radical cystectomy (RC) in bladder cancer patients. The aim of this study is to evaluate the oncological outcomes in patients who underwent RC with ERAS protocol.</p></div><div><h3>Methods</h3><p>We reviewed the records of patients who underwent RC for primary urothelial bladder carcinoma with curative intent from January 2003 to August 2022. The primary and secondary outcomes were recurrence-free (RFS) and overall survival (OS). Multivariable Cox regression analysis was performed to evaluate the effect of ERAS on oncological outcomes.</p></div><div><h3>Results</h3><p>A total of 967 ERAS patients and 1144 non-ERAS patients were included in this study. The RFS rates at 1, 3, and 5 years after RC were 81%, 71.5%, and 69% in the ERAS cohort, respectively. This rate in the non-ERAS group was 81%, 71%, and 67% at 1, 3, and 5 years after RC, respectively (P = 0.50). However, ERAS patients had significantly better OS with 86%, 73%, and 67% survival rates at 1, 3, and 5 years compared to 84%, 68%, and 59.5% survival rates in the non-ERAS group, respectively (P = 0.002). In multivariable analysis adjusting for other relevant factors, ERAS was no longer independently associated with recurrence-free (HR = 0.96, 95% CI 0.76–1.22, P = 0.75) or overall survival (HR = 0.84, 95% CI 0.66–1.09, P = 0.28) following RC.</p></div><div><h3>Conclusion</h3><p>ERAS protocols are associated with a shorter hospital stay, yet with no impact on long-term oncologic outcomes in patients undergoing RC for bladder cancer.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of enhanced recovery after surgery on oncologic outcome following radical cystectomy for urothelial bladder carcinoma\",\"authors\":\"Runzhuo Ma,&nbsp;Farshad Sheybaee Moghaddam,&nbsp;Alireza Ghoreifi,&nbsp;Sanam Ladi-Seyedian,&nbsp;Jie Cai,&nbsp;Gus Miranda,&nbsp;Monish Aron,&nbsp;Anne Schuckman,&nbsp;Mihir Desai,&nbsp;Inderbir Gill,&nbsp;Siamak Daneshmand,&nbsp;Hooman Djaladat\",\"doi\":\"10.1016/j.suronc.2024.102061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Limited data are available regarding the effect of enhanced recovery after surgery (ERAS) protocols on the long-term outcomes of radical cystectomy (RC) in bladder cancer patients. The aim of this study is to evaluate the oncological outcomes in patients who underwent RC with ERAS protocol.</p></div><div><h3>Methods</h3><p>We reviewed the records of patients who underwent RC for primary urothelial bladder carcinoma with curative intent from January 2003 to August 2022. The primary and secondary outcomes were recurrence-free (RFS) and overall survival (OS). Multivariable Cox regression analysis was performed to evaluate the effect of ERAS on oncological outcomes.</p></div><div><h3>Results</h3><p>A total of 967 ERAS patients and 1144 non-ERAS patients were included in this study. The RFS rates at 1, 3, and 5 years after RC were 81%, 71.5%, and 69% in the ERAS cohort, respectively. This rate in the non-ERAS group was 81%, 71%, and 67% at 1, 3, and 5 years after RC, respectively (P = 0.50). However, ERAS patients had significantly better OS with 86%, 73%, and 67% survival rates at 1, 3, and 5 years compared to 84%, 68%, and 59.5% survival rates in the non-ERAS group, respectively (P = 0.002). In multivariable analysis adjusting for other relevant factors, ERAS was no longer independently associated with recurrence-free (HR = 0.96, 95% CI 0.76–1.22, P = 0.75) or overall survival (HR = 0.84, 95% CI 0.66–1.09, P = 0.28) following RC.</p></div><div><h3>Conclusion</h3><p>ERAS protocols are associated with a shorter hospital stay, yet with no impact on long-term oncologic outcomes in patients undergoing RC for bladder cancer.</p></div>\",\"PeriodicalId\":51185,\"journal\":{\"name\":\"Surgical Oncology-Oxford\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-03-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgical Oncology-Oxford\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S096074042400029X\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology-Oxford","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S096074042400029X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言有关术后恢复强化方案(ERAS)对膀胱癌根治性膀胱切除术(RC)长期疗效的影响的数据有限。方法我们回顾了2003年1月至2022年8月期间因原发性尿路上皮膀胱癌接受根治性膀胱切除术的患者记录。主要和次要结果为无复发(RFS)和总生存率(OS)。本研究共纳入了 967 名 ERAS 患者和 1144 名非 ERAS 患者。ERAS组在RC后1年、3年和5年的RFS率分别为81%、71.5%和69%。非ERAS组在RC后1年、3年和5年的RFS率分别为81%、71%和67%(P = 0.50)。然而,ERAS 患者的 OS 明显更好,1、3 和 5 年的生存率分别为 86%、73% 和 67%,而非 ERAS 组的生存率分别为 84%、68% 和 59.5%(P = 0.002)。在调整了其他相关因素后进行的多变量分析中,ERAS 与膀胱癌 RC 术后无复发生存率(HR = 0.96,95% CI 0.76-1.22,P = 0.75)或总生存率(HR = 0.84,95% CI 0.66-1.09,P = 0.28)不再独立相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The effect of enhanced recovery after surgery on oncologic outcome following radical cystectomy for urothelial bladder carcinoma

Introduction

Limited data are available regarding the effect of enhanced recovery after surgery (ERAS) protocols on the long-term outcomes of radical cystectomy (RC) in bladder cancer patients. The aim of this study is to evaluate the oncological outcomes in patients who underwent RC with ERAS protocol.

Methods

We reviewed the records of patients who underwent RC for primary urothelial bladder carcinoma with curative intent from January 2003 to August 2022. The primary and secondary outcomes were recurrence-free (RFS) and overall survival (OS). Multivariable Cox regression analysis was performed to evaluate the effect of ERAS on oncological outcomes.

Results

A total of 967 ERAS patients and 1144 non-ERAS patients were included in this study. The RFS rates at 1, 3, and 5 years after RC were 81%, 71.5%, and 69% in the ERAS cohort, respectively. This rate in the non-ERAS group was 81%, 71%, and 67% at 1, 3, and 5 years after RC, respectively (P = 0.50). However, ERAS patients had significantly better OS with 86%, 73%, and 67% survival rates at 1, 3, and 5 years compared to 84%, 68%, and 59.5% survival rates in the non-ERAS group, respectively (P = 0.002). In multivariable analysis adjusting for other relevant factors, ERAS was no longer independently associated with recurrence-free (HR = 0.96, 95% CI 0.76–1.22, P = 0.75) or overall survival (HR = 0.84, 95% CI 0.66–1.09, P = 0.28) following RC.

Conclusion

ERAS protocols are associated with a shorter hospital stay, yet with no impact on long-term oncologic outcomes in patients undergoing RC for bladder cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Surgical Oncology-Oxford
Surgical Oncology-Oxford 医学-外科
CiteScore
4.50
自引率
0.00%
发文量
169
审稿时长
38 days
期刊介绍: Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.
期刊最新文献
Machine learning in cancer prognostication: Limitations and opportunities. Bilobed lateral artery perforator-based flap for partial breast reconstruction - Technique description and results from a ten-year cohort. Individualizing care for patients with gallbladder cancer Natural history of salivary gland secretory carcinoma: A REFCOR study. Tumor necrosis drives prognosis in osteosarcoma: No difference in chemotherapy response and survival between chondroblastic and osteoblastic osteosarcoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1